New cancer clinical trial: DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

Published on: April 23, 2018 at 12:00PM
Condition:   Non-Small Cell Lung Cancer
Intervention:   Drug: Trastuzumab deruxtecan (DS-8201a)
Sponsors:   Daiichi Sankyo, Inc.;   Daiichi Sankyo Co., Ltd.
Not yet recruiting
https://ift.tt/2HNY4c5